| Not Yet Recruiting | Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in NCT07494045 | OPKO Health, Inc. | Phase 2 |
| Completed | A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism NCT06877247 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Intraoperative Parathyroid Hormone Monitoring to Guide Surgery in Renal hyperparathyroIdism NCT06542315 | McMaster University | N/A |
| Not Yet Recruiting | The Effect of Increasing Dialysate Calcium on T50 in Subjects With Secondary Hyperparathyroidism and ESKD NCT06398002 | Iain Bressendorff | Phase 2 |
| Completed | The Trial of SHR6508 in Secondary Hyperparathyroidism NCT06434961 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 3 |
| Unknown | Quality of Life Change in Patients Undergoing Parathyroidectomy With End-stage Renal Failure NCT06378931 | Chunling Jiang | — |
| Active Not Recruiting | Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism NCT06130683 | China-Japan Friendship Hospital | — |
| Recruiting | A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj. NCT06126016 | Boryung Pharmaceutical Co., Ltd | — |
| Completed | Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 NCT05836220 | Pathalys Pharma | Phase 3 |
| Completed | Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1 NCT05832931 | Pathalys Pharma | Phase 3 |
| Unknown | A Study of SHR6508 in Secondary Hyperparathyroidism NCT05663411 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 2 |
| Completed | Diagnostic Accuracy of 3T MR for Secondary Hyperparathyroidism Comparison With 4DCT NCT05540795 | Fifth Affiliated Hospital, Sun Yat-Sen University | — |
| Terminated | Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathy NCT05543928 | OPKO Health, Inc. | Phase 3 |
| Recruiting | Precision Medicine Approaches to Renal Osteodystrophy NCT05880914 | Thomas Nickolas | — |
| Completed | A Trial of SHR6508 in Secondary Hyperparathyroidism NCT05221008 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 |
| Unknown | A Study to Assess the Efficacy and Safety of Paricalcitol in the Treatment of Chronic Kidney Disease With Seco NCT04994080 | Chengdu Suncadia Medicine Co., Ltd. | Phase 3 |
| Completed | Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). NCT04750460 | Saint Petersburg State University, Russia | Phase 3 |
| Completed | Changes in Cardiac Functions in Patients Treated With Parathyroidectomy for Secondary Hyperparathyroidism NCT06187480 | Mersin University | — |
| Recruiting | A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis NCT03969329 | Amgen | Phase 3 |
| Completed | Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients NCT03937349 | Saint Petersburg State University, Russia | — |
| Recruiting | A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disea NCT03633708 | Amgen | Phase 3 |
| Completed | Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia NCT03822507 | Kyowa Kirin Co., Ltd. | Phase 3 |
| Completed | Phase 3 Study of SK-1403 NCT03801980 | Sanwa Kagaku Kenkyusho Co., Ltd. | Phase 3 |
| Completed | SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving He NCT03626948 | Sanwa Kagaku Kenkyusho Co., Ltd. | Phase 3 |
| Completed | Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Ja NCT03660800 | OPKO Health, Inc. | Phase 1 |
| Completed | Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyr NCT03299244 | Amgen | Phase 3 |
| Completed | The Longitudinal PTH-Study NCT03464149 | Medical University of Vienna | — |
| Completed | A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416 NCT03283098 | Amgen | Phase 1 |
| Completed | Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients NCT03182699 | Rainer Oberbauer | Phase 4 |
| Completed | IOPTH Usefulness for Predicting Successful Surgery in Secondary Hyperparathyroidism NCT04484116 | Hospital General Ajusco Medio | — |
| Completed | Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism NCT03226171 | Sanwa Kagaku Kenkyusho Co., Ltd. | Phase 2 |
| Unknown | the Study on Prognostic for Hemodialysis Patients NCT03194087 | Beijing Friendship Hospital | — |
| Completed | Pathogenesis of Compromised Bone Quality and Mechanics in Chronic Kidney Disease NCT03626246 | Columbia University | — |
| Completed | Phase 3 Study of KHK7580 NCT02549417 | Kyowa Kirin Co., Ltd. | Phase 3 |
| Completed | Phase 3 Study of KHK7580 NCT02549404 | Kyowa Kirin Co., Ltd. | Phase 3 |
| Completed | Phase 3 Study of KHK7580 NCT02549391 | Kyowa Kirin Co., Ltd. | Phase 2 / Phase 3 |
| Unknown | Comparison of Total Parathyroidectomy With and Without Autotransplantation NCT02536287 | The Second Hospital of Anhui Medical University | Phase 3 |
| Unknown | The Effect of Diuretics on Mineral and Bone Disorder in Chronic Kidney Disease Patients NCT03082742 | University of Sao Paulo General Hospital | N/A |
| Unknown | The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Unde NCT02332135 | Wenhu Liu | N/A |
| Unknown | Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients NCT02338934 | Penang Hospital, Malaysia | Phase 4 |
| Completed | Phase 2 Study of KHK7580 NCT02216656 | Kyowa Kirin Co., Ltd. | Phase 2 |
| Completed | Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis NCT02143271 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Completed | A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis NCT02133404 | Astellas Pharma Inc | Phase 2 |
| Completed | Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy NCT03137316 | Benha University | — |
| Completed | Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet NCT01896232 | Amgen | Phase 3 |
| Terminated | Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol NCT01725113 | Winthrop University Hospital | Phase 4 |
| Completed | A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperpara NCT01653379 | Deltanoid Pharmaceuticals | Phase 2 |
| Terminated | Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-41 NCT01576146 | KAI Pharmaceuticals | Phase 2 |
| Completed | Morbidity Related to Secondary Hyperparathyroidism After Renal Transplantation NCT01741064 | Skane University Hospital | — |
| Completed | Etelcalcetide to Treat Secondary Hyperparathyroidism in Hemodialysis Patients With Chronic Kidney Disease-Mine NCT01414114 | KAI Pharmaceuticals | Phase 2 |
| Completed | A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chron NCT01382212 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Withdrawn | Effects of Vitamin D on Renal Blood Flow, Proteinuria and Inflammation in Patients With Chronic Kidney Disease NCT01426724 | University of Virginia | N/A |
| Unknown | Intravenous Paricalcitol in Chronic Hemodialysis Patients NCT03023748 | The University of Hong Kong | Phase 4 |
| Withdrawn | Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Device to Treat Secondary Hyperparathyroidism NCT01421407 | Theraclion | N/A |
| Completed | Quality of Life in Greek Hemodialysis Patients Receiving Zemplar Intravenous NCT01368042 | AbbVie (prior sponsor, Abbott) | — |
| Completed | Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on NCT01401478 | AbbVie (prior sponsor, Abbott) | — |
| Completed | A Study to Follow-up Patients With End Stage Renal Disease Undergoing Hemodialysis, Receiving Selective Vitami NCT01149291 | AbbVie (prior sponsor, Abbott) | — |
| Terminated | Pediatric Chronic Kidney Disease Safety and Efficacy NCT01277510 | Amgen | Phase 3 |
| Completed | Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chro NCT01341782 | AbbVie (prior sponsor, Abbott) | Phase 3 |
| Completed | Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism NCT01254565 | KAI Pharmaceuticals | Phase 2 |
| Completed | Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment o NCT01265992 | AbbVie (prior sponsor, Abbott) | — |
| Completed | Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease NCT01290029 | Amgen | Phase 1 |
| Completed | Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) NCT01224782 | AbbVie (prior sponsor, Abbott) | — |
| Completed | Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) NCT01219855 | OPKO Health, Inc. | Phase 2 / Phase 3 |
| Completed | Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level NCT01101113 | Seoul National University Hospital | Phase 4 |
| Completed | LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism P NCT01167309 | LEO Pharma | Phase 1 |
| Terminated | Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease NCT01134315 | AbbVie (prior sponsor, Abbott) | — |
| Completed | Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients NCT01447368 | The University of Hong Kong | Phase 4 |
| Completed | Trial to Optimize Mineral Outcomes in Dialysis Patients NCT01100723 | University of Colorado, Denver | Phase 4 |
| Unknown | Cinacalcet in Paediatric Secondary Hyperparathyroidism (SHPT) Due to Chronic Kidney Disease (CKD) NCT01479088 | ENRICO VERRINA | Phase 2 / Phase 3 |
| Completed | Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mi NCT01025128 | Clalit Health Services | Phase 4 |
| Terminated | Effect of Vitamin D Supplement on Inflammation Markers in High-Risk Cardiovascular Patients With Chronic Kidne NCT01012414 | Thomas Jefferson University | Phase 3 |
| Completed | Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation NCT01178450 | Josep M Cruzado | Phase 4 |
| Completed | Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet With Low-Dose Vitamin D NCT00977080 | Abbott | Phase 4 |
| Completed | Paricalcitol Compared to Maxacalcitol in Chronic Kidney Disease Patients With Secondary Hyperparathyroidism NCT00990704 | Abbott | Phase 2 |
| Completed | FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease NCT00999037 | University of California, Los Angeles | N/A |
| Completed | Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Tran NCT01220050 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Completed | Vitamin D Deficiency in Chronic Kidney Disease (CKD) Patients NCT00958451 | Salem Veterans Affairs Medical Center | Phase 4 |
| Completed | Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience NCT01083186 | AbbVie (prior sponsor, Abbott) | — |
| Completed | Effectiveness and Safety of IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Usin NCT00891813 | Abbott | Phase 4 |
| Completed | Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic K NCT00888069 | OPKO IP Holdings II, Inc. | Phase 1 |
| Completed | 20070360 Incident Dialysis NCT00803712 | Amgen | Phase 4 |
| Completed | Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3/4 Chronic Kidney Disease (CKD) With Secondar NCT00823303 | Washington University School of Medicine | Phase 4 |
| Terminated | Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant NCT00664430 | Abbott | Phase 4 |
| Completed | Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With NCT01073462 | AbbVie (prior sponsor, Abbott) | — |
| Completed | Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Se NCT00792857 | OPKO IP Holdings II, Inc. | Phase 1 |
| Completed | Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease NCT00742716 | OPKO IP Holdings II, Inc. | Phase 2 |
| Completed | Efficacy and Safety of Alfacalcidol Compared to Calcitriol for Treatment of Secondary Hyperparathyroidism NCT01115543 | Mahidol University | Phase 4 |
| Completed | Long-term Safety Study of Paricalcitol Injection in Chronic Kidney Disease Patients With Hemodialysis (HD) NCT00701805 | Abbott | Phase 2 |
| Completed | Dose-response Study of Paricalcitol Injection in Chronic Kidney Disease Patients Receiving Hemodialysis NCT00667576 | Abbott | Phase 2 |
| Completed | Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and NCT01083849 | AbbVie (prior sponsor, Abbott) | — |
| Completed | Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT) NCT00828347 | Kumamoto University | N/A |
| Completed | Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyper NCT00537979 | Abbott | Phase 4 |
| Terminated | Treatment of Secondary Hyperparathyroidism in the Uremic Patient NCT00469599 | Zealand University Hospital | N/A |
| Completed | A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection NCT00463021 | Genzyme, a Sanofi Company | Phase 4 |
| Terminated | Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients NCT00415584 | Montefiore Medical Center | Phase 1 / Phase 2 |
| Completed | A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis NCT00454350 | Genzyme, a Sanofi Company | Phase 4 |
| Completed | Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism NCT00754442 | University of Maryland, Baltimore | N/A |
| Completed | Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyr NCT01081665 | Abbott | — |
| Completed | A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis NCT00418600 | Genzyme, a Sanofi Company | Phase 4 |
| Completed | ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chron NCT00379899 | Amgen | Phase 4 |
| Completed | A Study of Cinacalcet to Improve Achievement of National Kidney Foundation Kidney Disease Outcomes Quality Ini NCT00431496 | Amgen | Phase 4 |
| Completed | E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events NCT00345839 | Amgen | Phase 3 |
| Terminated | Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis NCT00446329 | Papageorgiou General Hospital | Phase 4 |
| Completed | A Study of Zemplar® Injection and Hectorol® Injection on Intestinal Absorption of Calcium in Chronic Kidney Di NCT00257920 | Abbott | Phase 4 |
| Completed | Bone Biopsy Study For Dialysis Patients With Secondary Hyperparathyroidism of End Stage Renal Disease NCT00261950 | Amgen | Phase 2 |
| Completed | Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity NCT00288873 | Weill Medical College of Cornell University | Phase 4 |
| Completed | Post Transplant Study NCT00395902 | Amgen | — |
| Completed | ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism NCT00135304 | Amgen | Phase 4 |
| Completed | Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Sec NCT00123461 | Genzyme, a Sanofi Company | Phase 4 |
| Completed | Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism NCT00307840 | Papageorgiou General Hospital | Phase 4 |
| Completed | SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism NCT00117052 | Amgen | Phase 3 |
| Completed | Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium NCT00073710 | Abbott | Phase 4 |
| Completed | START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary NCT00132431 | Amgen | Phase 4 |
| Completed | Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions NCT00601328 | Roxane Laboratories | N/A |
| Completed | Study for Secondary Hyperparathyroidism in Chronic Renal Insufficiency Patients NCT00042432 | Amgen | Phase 2 |
| Completed | A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dia NCT00042653 | Amgen | Phase 3 |
| Completed | Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodial NCT00053547 | Abbott | Phase 4 |
| Terminated | Active Vitamin D Effect on Left Ventricular Hypertrophy NCT00175149 | Per Ivarsen | Phase 4 |
| Completed | A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patien NCT00037635 | Amgen | Phase 3 |
| Completed | Regulation of Bone Formation in Renal Osteodystrophy NCT00560300 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 2 |
| Completed | Calcium and Vitamin D Malnutrition in Elderly Women NCT00352170 | Creighton University | Phase 3 |
| Completed | Acute Regulation of Parathyroid Hormone by Dietary Phosphate NCT00037193 | National Center for Research Resources (NCRR) | — |